A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

• ClinicalTrials.gov Identifier: NCT05626803
• Recruitment Status: Active, not recruiting
• First Posted: November 25, 2022
• Last Update Posted: March 15, 2024
• Sponsor: Vaxart
• Information provided by (Responsible Party): Vaxart

Tracking Information

• First Submitted Date: November 15, 2022
• First Posted Date: November 25, 2022
• Last Update Posted Date: March 15, 2024
• Actual Study Start Date: February 28, 2022
• Actual Primary Completion Date: October 16, 2023 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: November 6, 2023)

• The safety of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Frequency, duration and severity of Solicited Symptoms of Reactogenicity (GI and systemic) [ Time Frame: Up to 1 week ]
• The safety of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Frequency, duration, and severity of unsolicited adverse events (AEs) [ Time Frame: Up to 28 days ]
• The safety of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Frequency, duration, and severity of serious adverse event (SAEs). [ Time Frame: Up to Day 180 ]
• The safety of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Frequency, duration, and severity of adverse event of special interest (AESIs). [ Time Frame: Up to Day 180 ]
• The safety of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Frequency, duration, and severity of New Onset of Chronic Illness (NOCIs). [ Time Frame: Up to Day 180 ]
• The immunogenicity of a bivalent dosing regimen of GI.1 and GII.4. Parameter: Geometric mean concentration (GMC) of Serum -Anti-VP1 GI.1 IgG, Anti-VP1 GII.4 and BT50 for both vaccine [ Time Frame: Up to Day 29 ]
• The immunogenicity of a bivalent dosing regimen of GI.1 and GII.4. Parameter: Geometric mean fold rise (GMFR) of Serum -Anti-VP1 GI.1 IgG, Anti-VP1 GII.4 and BT50 for both vaccine [ Time Frame: Up to Day 29 ]

Original Primary Outcome Measures (submitted: November 15, 2022)

• To determine the safety of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Frequency, duration and severity of Solicited Symptoms of Reactogenicity (GI and systemic) [ Time Frame: Up to 1 week ]
• To determine the safety of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Frequency, duration, and severity of unsolicited adverse events (AEs) [ Time Frame: Up to 28 days ]
• To determine the safety of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Frequency, duration, and severity of serious adverse event (SAEs). [ Time Frame: Up to 1 year ]
• To determine the safety of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Frequency, duration, and severity of adverse event of special interest (AESIs). [ Time Frame: Up to 1 year ]
• To determine the safety of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Frequency, duration, and severity of New Onset of Chronic Illness (NOCIs). [ Time Frame: Up to 1 year ]
• To determine the immunogenicity of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Geometric mean concentration (GMC) of Serum -Anti IgA for both vaccines [ Time Frame: On Day 29 ]
• To determine the immunogenicity of a bivalent dosing regimen of GI.1 and GII.4, to select the dose level with which to safely proceed into Phase 3 development. Parameter: Geometric mean fold rise (GMFR) of Serum -Anti IgA for both vaccines [ Time Frame: Up to Day 29 ]

• Current Secondary Outcome Measures: Not Provided
• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers
• Official Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Single Dose, Dose-ranging Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccine Administered Orally to Healthy Volunteers Aged Greater Than or Equal to 18 Years and Less Than or Equal to 80 Years Old.
• Brief Summary: This study is designed to evaluate the safety and immunogenicity of two monovalent Norovirus (NoV) oral tableted vaccine candidates, VXA-G1.1-NN and VXA-GII.4-NS co-administered (bivalent delivery) against a matching placebo arm. Bivalent GI.1 and GII.4 vaccines are being investigated for the prevention of noroviral gastroenteritis caused by norovirus GI.1 and GII.4.

Detailed Description

Norovirus infections are a leading cause of sporadic and epidemic gastroenteritis across all age groups worldwide. This study is designed as a standard double-blind placebo-controlled single administration, dose ranging study to evaluate the safety and immunogenicity of 2 different doses of VXA-GII.4-NS plus VXA-G1.1-NN (high and medium dose administered orally for the prevention of Norovirus infection), compared with a placebo.

This study will enroll a total of 135 subjects with10 sentinel subjects in an open label period (dosing staggered to not-more-than 2 subjects per 24 hours) and randomize 125 subjects in three arms.

The first 10 sentinel subjects will receive the open label high dose of active vaccine. If no dose-related toxicities are observed, and upon the recommendation of the SMC following review of safety data, subjects will be randomized in a 2:2:1 ratio to one of the 3 study arms to receive active vaccine or placebo. After vaccination on Day 1, the study will include an Active Study Period that runs through 4 weeks after administration (Day 29), and a Follow-up Period of one year for safety and duration of immune response.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Prevention
• Condition: Norovirus Infections

Intervention

• Drug: Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose
  The first 10 sentinel subjects will receive open label high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
• Drug: Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose
  50 subjects will receive high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
• Drug: Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose
  50 subjects will receive Bivalent GII.4/GI.1 medium dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 5×10 to the power 10 tablets; total dose is 1×10 to the power 11 IU/dose
• Drug: Placebo
  25 subjects will receive matching placebo

Study Arms

• Experimental: Open Label Sentinel
  Bivalent GII.4/GI.1 vaccine Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets total dose is 2×10 to the power 11 IU/dose (sentinel n=10)
  Intervention: Drug: Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose
• Experimental: Medium Dose Arm
  Bivalent GII.4/GI.1 vaccine Bivalent GII.4/GI.1 medium dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 5×10 to the power 10 tablets total dose is 1×10 to the power 11 IU/dose (N=50)
  Intervention: Drug: Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose
• Experimental: High Dose Arm
  Bivalent GII.4/GI.1 vaccine Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets total dose is 2×10 to the power 11 IU/dose (N=50)
  Intervention: Drug: Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose
• Placebo Comparator: Placebo Arm
  Placebo tablets (N= 25)
  Intervention: Drug: Placebo

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: July 28, 2023): 135
• Original Estimated Enrollment (submitted: November 15, 2022): 623
• Estimated Study Completion Date: July 31, 2024
• Actual Primary Completion Date: October 16, 2023 (Final data collection date for primary outcome measure)

Eligibility Criteria

Key Inclusion Criteria:

To be eligible for this study, subjects must meet all the following:

1. In stable and good general health, without significant medical illness, based on medical history, physical examination, and vital signs at screening based on investigator judgement.
2. Body mass index (BMI) between >/= 17.0 and </= 35.0 kg/m2 at screening SNG.
3. Available for all planned visits and tele-health appointment, and willing to complete all protocol-defined procedures and assessments (including ability and willingness to swallow multiple small enteric-coated tablets per study dose).
4. Female subjects must not be breastfeeding and must provide a negative pregnancy test at screening and pre-dose.

5. Female subjects must fulfill one of the following criteria:

   i. At least 1 year post-menopausal (defined as amenorrhea for greater than or equal to 12 consecutive months prior to screening without alternative medical cause) or surgically sterile.

   ii. Female subjects of childbearing potential must be willing to use a highly effective form of contraception for 30 days prior to initial vaccination and until 60 days after last vaccination. Acceptable forms are oral, implantable, intrauterine, transdermal, intravaginal, injectable, double barrier or abstinence (subjects using diaphragms must also use condom). The form of contraception must be approved by the investigator.

   iii. Male subjects must agree to practice abstinence from heterosexual intercourse or to use an effective method of birth control as noted above from first vaccination to 60 days after last vaccination. Male subjects must agree to refrain from donating sperm and practice abstinence from all intercourse or to use an effective method of double barrier birth control or condom as noted above from first vaccination to 60 days after last vaccination.

6. Capable of understanding and giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.

Key Exclusion Criteria:

The subjects must be excluded from participating in the study if they meet any of the following:

1. Known clotting/bleeding issues and/or personal and family history with increased risk of bleeding or clotting.
2. Presence of significant uncontrolled medical or psychiatric illness (acute or chronic) including institution of new medical/surgical treatment or significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months prior to screening and reconfirmed at baseline.
3. Cancer, or treatment for cancer or any procedure or preventive medication for cancer or to prevent recurrence, within past 3 years (excluding fully treated and resolved basal cell carcinoma or squamous cell carcinoma)
4. Presence of immunosuppression or medical condition possibly associated with impaired immune responsiveness, including diabetes mellitus- type 1 and 2

5. History of irritable bowel disease or other inflammatory digestive or gastrointestinal condition that could affect the distribution/safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine. Such conditions may include but are not limited to:

   a. Any history of: i. GI malignancy ii. malabsorption iii. pancreatobiliary disorders iv. inflammatory bowel disease v. irritable bowel disease vi. hiatal hernia vii. surgical resection b. History of diagnosis or treatment in past 5 years of: i. esophageal or gastric motility disorder ii. gastro esophageal reflux disorder iii. peptic ulcer iv. cholecystectomy

6. History of any form of angioedema
7. History of serious reactions to vaccination such as anaphylaxis, respiratory problems, hives or abdominal pain
8. Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws problematic.
9. Any condition that resulted in the absence or removal of the spleen
10. Acute disease within 72 hours prior to vaccination defined as the presence of a moderate or severe illness (as determined by the investigator through medical history and physical exam). (Assessment may be repeated once during Screening Period)
11. Presence of a fever greater than or equal to 38°C measured orally at baseline.
12. Any significant hospitalization within the last year which in the opinion of the investigator or sponsor could interfere with study participation.

13. Any history or conditions that may lead to higher risk of clotting events and/or thrombocytopenia:

    1. Family or personal history of bleeding or thrombosis.
    2. History of heparin-related thrombotic events, and/or receiving heparin treatments.
    3. History of autoimmune or inflammatory disease.
    4. Presence of any of the following conditions known to increase risk of thrombosis within 6 months prior to screening:

    i. Recent surgery other than removal/biopsy of cutaneous lesions ii. Immobility (confined to bed or wheelchair for 3 or more successive days) iii. Head trauma with loss of consciousness or documented brain injury iv. Receipt of anticoagulants for prophylaxis of thrombosis v. Recent clinically significant infection, including hospitalization for COVID-19 infection.

14. Any other condition that in the clinical judgement of the investigator would jeopardize the safety or rights of a subject taking the study drug, would render the subject unable to comply within the protocol or would interfere with the evaluation of the study endpoints diagnostic assessments.
15. Positive human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg) or Hepatitis C virus (HCV) tests at the screening visit.
16. History of GI bleeding including hematochezia (blood in stool) or melena (black stool)
17. Positive urine drug screen for drugs of abuse at screening (positive test for marijuana is not exclusionary; however concurrent use of marijuana during the study Active period through Day 29 is prohibited).
18. Positive breath or urine alcohol test at screening and baseline.
19. Receipt of a licensed vaccine (including any COVID-19 vaccines under emergency use authorization) within 14 days prior to baseline vaccination or planned administration during the study active period (Day 29).
20. Use of antibiotics, proton pump inhibitors, H2 blockers or antacids within 7 days prior to study drug administration or planned use during the active study period (Day 29).
21. Use of medications known to affect the immune function (e.g., including but not limited to systemic corticosteroids, leukotriene modifiers, and JAK inhibitors) within 2 weeks before study drug administration or planned use during the active study period (Day 29).
22. Daily use of nonsteroidal anti-inflammatory drugs within 7 days prior to study drug administration or planned use during the active study period (Day 29). Low dose daily ASA less than or equal to 100 mg for cardio-protection is not exclusionary.
23. Administration of any investigational vaccine, drug or device within 8 weeks preceding study drug administration, or planned use within the duration of the study
24. Previous participation in a Vaxart Clinical Trial or other NoV vaccine trial unless confirmed receipt of placebo.
25. Donation or use of blood or blood products within 30 days prior to study drug administration or planned donation during the active study period (Day 29).
26. History of drug, alcohol, or chemical abuse within 1 year of screening.
27. History of hypersensitivity or allergic reaction to any component of the investigational vaccine, including but not limited to fish gelatin allergy.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 80 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States
• Removed Location Countries: New Zealand

Administrative Information

• NCT Number: NCT05626803
• Other Study ID Numbers: VXA-NVV-202
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Vaxart
• Original Responsible Party: Same as current
• Current Study Sponsor: Vaxart
• Original Study Sponsor: Same as current
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: Vaxart
• Verification Date: January 2024